Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 1 results out of 1
Data Insights
ALEC-04 by Alentis Therapeutics for Recurrent Head And Neck Squamous Cell Carcinoma: Likelihood of Approval
ALEC-04 is under clinical development by Alentis Therapeutics and currently in Phase II for Recurrent Head And Neck Squamous Cell...